Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR vs Octreotide LAR in Metastatic Carcinoid Tumors with Inadequate Symptom Control
2007-000739-25Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2007
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Carcinoid Tumor (CT) comparing Pasireotide LAR with Octreotide LAR (2 arms). Started Dec 2007; status: terminated.
02
Drugs
pasireotide LARoctreotide
03
Conditions
Carcinoid Tumor (CT)
Beyond the preview
Go deeper on 2007-000739-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000739-25.